Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVPH -- INNOVIVE Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: bookert11 who wrote (76)	2/20/2008 5:34:13 PM
From: stunner	Respond to of 117

Buyout is raised as a possibility in the SEC filing does because it mentions vesting of options to employees upon either a raise of a buyout. I have to imagine that the raise collapsed for some reason-- perhaps the target raise was too high? But now, what would be the strike price-- $0.5, $1, $1.5? Obviously, the stock was above $4 when they had the same drugs with similar phase I data but actually had $$ on hand. Now, they are at bankruptcy price and to do a raise at this level may not be best for shareholders, unless of course you are a party to the raise. If I were a fledging biotech perhaps with one really interesting drug in PII/III, a market cap of $250-300M, and not much else to hang my hat on in the case of PIII failure, I would be strongly thinking about picking up this pipeline for $30M ($2 a share). Especially, since this would probably add that much value to the co's market cap.